Because of the modest efficacy of dopamine agonists in acromegaly, cabergoline monotherapy can be considered as first-line medical therapy only for those with modestly elevated GH and IGF-1 levels (IGF-1 < 2.5 × ULN) (4, 13, 14). The gene discussed is IGF1; the disease is acromegaly.